XML 67 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Based Compensation Plans
6 Months Ended
Jun. 30, 2013
Stock Based Compensation Plans [Abstract]  
Stock Based Compensation Plans
NOTE IStock Based Compensation Plans:
 
As more fully discussed in Note 11 of the notes to the consolidated financial statements in our 2012 Annual Report on Form 10-K, we have options and awards outstanding for Common Stock under two stock-based employee compensation plans.
 
The following table summarizes our share option and award activity during the six months ended June 30, 2013:
Restricted Stock Awards
Stock-Settled
Appreciation Rights
Options
Shares or Units
Weighted-Average
Award Price
Rights
Weighted-Average
Award Price
Shares
Weighted-Average
Exercise Price
Outstanding at December 31, 2012
555,925$12.28121,749$8.8550,000$20.56
Granted
161,15018.13112,00018.14
Exercised or restrictions lapsed
(277,475)12.24(72,049)8.94(30,000)$20.75
Forfeited or expired (options)
(2,350)14.56(2,000)$15.90
Outstanding at June 30, 2013
437,250$14.45161,700$15.2518,000$20.75
Exercisable at June 30, 2013
49,7008.7218,000$20.75

Grants of restricted common stock and stock-settled appreciation rights are made to certain officers and key employees under the 2004 LTIP Plan. The restrictions on the awards generally lapse annually, primarily over four year periods. The compensation is being charged to selling, general and administrative expense over the respective grants’ vesting periods, primarily on a straight-line basis. Stock based compensation expense for the six months ended June 30 was approximately $2.0 million in 2013 and $1.3 million in 2012. The aggregate intrinsic value of outstanding restricted common stock grants was $10.1 million at June 30, 2013. The aggregate intrinsic value of vested and outstanding stock-settled appreciation rights at June 30, 2013 was approximately $0.7 million and $1.3 million, respectively.
 
As of June 30, 2013, the remaining unamortized compensation cost related to unvested equity awards was approximately $5.7 million and scheduled to be recognized over a weighted-average period of 2.9 years.